Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GRK2 | P25098 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179906 | 1.00 | LMNA (0.51) | LMNAPPME1EGFRERBB2NLRP3 | |
| SCHEMBL4179908 | 1.00 | LMNA (0.51) | LMNAPPME1EGFRERBB2NLRP3 | |
| SCHEMBL4183775 | 0.89 | LMNA (0.58) | LMNAPPME1EGFRERBB2POLB | |
| SCHEMBL4183778 | 0.89 | LMNA (0.58) | LMNAPPME1EGFRERBB2POLB | |
| SCHEMBL4183780 | 0.89 | LMNA (0.58) | LMNAPPME1EGFRERBB2POLB | |
| SCHEMBL4169998 | 0.88 | LMNA (0.39) | LMNAPPME1EGFRERBB2NLRP3 | |
| SCHEMBL4169994 | 0.88 | LMNA (0.39) | LMNAPPME1EGFRERBB2NLRP3 | |
| SCHEMBL4169999 | 0.88 | LMNA (0.39) | LMNAPPME1EGFRERBB2NLRP3 | |
| SCHEMBL4191978 | 0.85 | LMNA (0.48) | LMNAEGFRERBB2POLBALDH1A1 | |
| SCHEMBL4191974 | 0.85 | LMNA (0.48) | LMNAEGFRERBB2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191193-A1 | Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof | ARSA, STS, SULT2A1 | LMNA 4621/4885PPME1 2181/4885EGFR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.